Clinical trials: Peg-IFNα
Chronic Hepatitis B
A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B
This is a randomized, open-label, multicenter phase II study to evaluate the efficacy and safety of BW-20507 in combination with PEG-IFNα in CHB patients
- Trial name
- HBV (NCT07135349)
- Testing
- BW-20507 with/without NUC, BW-20507 with/without NUC, Peg-IFNa
- Where
- 18 sites in China
- Volunteers
- 209 people
- Sponsor
- Shanghai Argo Biopharmaceutical Co., Ltd.
For Treatment of Chronic Hepatitis B Virus Infection
Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)
This study will evaluate the efficacy and safety of the regimens containing BRII-179, BRII-835, and PEG-IFNα in adult participants with chronic hepatitis B virus (HBV) infection receiving nucleos(t)ide reverse transcriptase…
- Trial name
- NCT06491563
- Testing
- BRII-179, BRII-835 (VIR-2218), PEG-IFNα
- Where
- 12 sites in China
- Volunteers
- 150 people
- Sponsor
- Brii Biosciences Limited
Chronic Hepatitis B Virus Infection
Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients
This study will evaluate the efficacy and safety of PEG-IFNα alone or in combination with different dose levels of BRII-835 (VIR-2218) in participants with chronic hepatitis B virus (HBV) infection.
- Trial name
- NCT05970289
- Testing
- PEG-IFNα, BRII-835
- Where
- 28 sites in Australia, China and 3 more
- Volunteers
- 86 people
- Sponsor
- Brii Biosciences Limited
Chronic Hepatitis B, Anti-PD-1 Antibody
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (B)
Hepatitis B virus (HBV) infection is a major public health threat in China. At present, a functional cure, also known as clinical cure or sustained Hepatitis B surface antigen (HBsAg) loss, is recommended as the ideal endpoint of…
- Conditions
- Chronic Hepatitis B, Anti-PD-1 Antibody, Anti-PD-L1 Antibody, Peg-IFNα
- Trial name
- NCT07845058
- Testing
- anti-PD-1/anti-PD-L1 antibody, NAs, PEG-IFNα
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Chronic Hepatitis B Virus (HBV) Infection
A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)
This Phase 2, randomized, double-blind study will evaluate the clinical efficacy and safety of the combination therapy of BRII-179, BRII-835, plus PEG-IFNα compared to PEG-IFNα in adult participants with chronic HBV infection…
- Trial name
- NCT06650852
- Testing
- BRII-179, BRII-835 (VIR-2218), PEG-IFNα
- Where
- 14 sites in China
- Volunteers
- 250 people
- Sponsor
- Brii Biosciences Limited
Hepatitis B, Chronic
Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
This is a phase 2 study in which participants with chronic hepatitis B virus (HBV) infection will receive VIR-2218, VIR-3434 and/or PEG-IFNα and be assessed for safety, tolerability, and efficacy
- Trial name
- MARCH (NCT04856085)
- Testing
- VIR-2218, VIR-3434, PEG-IFNα
- Where
- 37 sites in United States, Canada and 10 more
- Volunteers
- 244 people
- Sponsor
- Vir Biotechnology, Inc.
Chronic Hepatitis B
Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients
This is a prospective study to evaluate the safety and efficacy of Sintilimab (PD-1 antibody) in sequential combination with Peg-IFNα-2b in NA-supressed CHB patients who had previously received Peg-IFNα therapy.
- Trial name
- NCT06457477
- Testing
- Sintilimab, NAs, Peg-IFNα-2b
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Beijing 302 Hospital
Chronic Hepatitis B
The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients
This is a prospective, open-labled, randomized controlled study to assess efficacy and safety of treatment with Sintilimab (PD-1 antibody) combined Peg-IFNα-2b in CHB patients on stable NAs treatment.
- Trial name
- NCT06357806
- Testing
- Sintilimab, Peg-IFNα-2b, NAs
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Beijing 302 Hospital
Chronic Hepatitis b, Anti-PD-1 Antibody
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)
Hepatitis B virus (HBV) infection is a major public health threat in China. At present, a functional cure, also known as clinical cure or sustained Hepatitis B surface antigen (HBsAg) loss, is recommended as the ideal endpoint of…
- Conditions
- Chronic Hepatitis b, Anti-PD-1 Antibody, Peg-IFNα
- Trial name
- NCT05771402
- Testing
- Anti-PD-1 antibody, NAs, Peg-IFNα
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University